| P2093 | author name string | S Sherry | |
| P2860 | cites work | Impact of thrombolytic therapy on left ventricular mural thrombi in acute myocardial infarction | Q70398136 |
| | Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase | Q33447121 |
| | Thrombolytic therapy: current status (1). | Q39640542 |
| | Thrombolytic therapy: current status (2). | Q39643138 |
| | Streptokinase for the treatment of acute myocardial infarction: a brief review of randomized trials | Q39674483 |
| | The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow | Q41640497 |
| | Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase | Q42086134 |
| | Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction | Q43595052 |
| | Myocardial reperfusion: is it ever too late? | Q43783126 |
| | Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarction | Q44109984 |
| | Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? | Q44265182 |
| | Intravenous urokinase in acute myocardial infarction | Q44514108 |
| | Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen | Q45138182 |
| | Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function | Q47173605 |
| | The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs | Q47325541 |
| | Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. | Q54135542 |
| | Effect of early systemic thrombolytic therapy on left ventricular mural thrombus formation in acute anterior myocardial infarction | Q58072111 |
| | Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase | Q68137249 |
| | A double-blind randomized multicenter dose-ranging trial of intravenous streptokinase in acute myocardial infarction | Q68926608 |
| | Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study | Q69009918 |
| | Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction | Q69172782 |
| | Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction | Q69183950 |
| | High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation | Q69534973 |
| | Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator | Q69859494 |
| | Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials | Q69908517 |
| | Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS) | Q70196897 |
| | Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial Infarction | Q70303248 |
| | The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial | Q70331348 |
| | Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction | Q70357943 |
| | Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial | Q70398132 |
| P433 | issue | 2 | |
| P921 | main subject | thrombolysis | Q1931577 |
| P304 | page(s) | 103-109 | |
| P577 | publication date | 1991-01-01 | |
| P1433 | published in | Texas Heart Institute Journal | Q26841976 |
| P1476 | title | Thrombolytic therapy for acute myocardial infarction. Lessons to be learned | |
| P478 | volume | 18 | |